• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Global Nuclear Medicine Market in PET/SPECT Imaging and Therapy - Competitive Landscape, Current trends and Forecasts (2010 – 2015) - Product Image

Global Nuclear Medicine Market in PET/SPECT Imaging and Therapy - Competitive Landscape, Current trends and Forecasts (2010 – 2015)

  • Published: August 2011
  • Region: Global
  • 255 Pages
  • Markets and Markets

Global Nuclear Medicine (Medical Isotopes/ Radioisotopes/ Radiopharmaceuticals) Market in PET/SPECT Imaging and Therapy - Competitive Landscape, Current trends and Forecasts (2010 – 2015)

Radiopharmaceuticals Therapy and PET/SPECT Imaging – A Global Scenario (2010-2015)

Radiopharmaceuticals are pharmaceutical agents used to diagnose certain medical problems such as cardiac, cancer, neurology, and/or treat certain conditions such as cancers. The use of radiopharmaceuticals as tracer dates back to 1930's. Over the years, technical advancement in production, diagnostic equipments (SPECT and PET), and discovery of new radiopharmaceutical have driven the market. The global radiopharmaceuticals market for therapy and PET & SPECT imaging was valued at $3,213 million in 2010 and is expected to reach $4,734 million by 2015; growing at a CAGR of 8.1% from 2010 to 2015. The PET & SPECT diagnosis accounted for the largest share -90%- of the global radiopharmaceutical market.

Diagnostic applications of radiopharmaceuticals have around 90% of the market share. The market is growing due to the increasing incidences of cancer and cardiac diseases, requisition READ MORE >

Executive Summary

Market Scenario



1 Introduction

1.1 Key Take-Aways

1.2 Report Description

1.3 Markets Covered

1.4 Stakeholders

1.5 Research Methodology



2 Summary



3 Market Overview

3.1 Definition Of Radiopharmaceuticals

3.2 Evolution

3.3 Market Segmentation

3.4 Driving Force Analysis

3.4.1 Drivers

3.4.1.1 Increasing Incidence Of Cancer And Cardiac Ailments

3.4.1.2 Increasing Use Of Spect And Pet Scans

3.4.1.3 Rising Awareness Of Radiopharmaceuticals Among Physicians

3.4.1.4 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment

3.4.1.5 Ready Availability Of Radiopharmaceuticals From Cyclotrons

3.4.2 Restraints

3.4.2.1 Half-Life Of Radiopharmaceuticals

3.4.2.2 High Capital Demand

3.4.2.3 Lack Of Good Manufacturing Practices (Gmp)

3.4.2.4 Inefficient Effluent Treatment Management

3.4.2.5 Stringent Regulatory Guidelines

3.4.3 Threat

3.4.3.1 Shutdown Of Nuclear Reactors Impacts The Production Of Radioisotopes

3.4.4 Opportunities

3.4.4.1 Increasing Demand For Diagnosis

3.4.4.2 High Demand In Geographies With Inadequate Supply

3.5 Winning Imperatives

3.5.1 Introduction Of New Agents For The Treatment Of Alzheimer’S Disease

3.5.2 Increasing Regulatory Approvals Of Radiopharmaceuticals

3.6 Burning Issues

3.6.1 High Cost Of Imaging Devices

3.6.2 Shortage In Supply Of Technetium-99M (Radioisotope)

3.7 Market Share Analysis

3.8 End-User Analysis

3.9 Competitive Analysis

3.10 Patent Analysis

3.11 Future Radiopharmaceuticals



4 Radiopharmaceutical Market, By Isotopes

4.1 Introduction

4.2 Fludeoxyglucose (18F)

4.2.1 Increase In Availability Of Hybrid Pet/Ct Machines

4.2.2 Rise In Pet Procedures Increases Demand For Fdg

4.2.3 High Generation Costs Of Fdg

4.2.4 Need For Speedy & Efficient Transportation

4.3 Technetium (99Mtc)

4.3.1 Technetium Can Combine With 31 Different Carrier Molecules

4.3.2 Lack Of Availability Of Technetium

4.4 Thallium (201Tl)

4.4.1 Thallium Most Common Substitute Of Technetium

4.5 Gallium (67Ga)

4.6 Sodium Iodide (123I)

4.7 Iobenguane (131I)

4.8 Rhenium (186Re)

4.9 Samarium (153Sm)

4.10 Yttrium (90Y)

4.11 Erbium (169Er)

4.12 Others



5 Radiopharmaceutical Market, By Routes Of Administration (Roa)

5.1 Introduction

5.2 Intravenous Administration

5.3 Inhalation Administration

5.4 Peroral Administration

5.5 Other Routes Of Administration



6 Radiopharmaceutical Market, By Applications

6.1 Introduction

6.2 Radiopharmaceuticals For Diagnosis

6.2.1 Single-Photon Emission Computed Tomography (Spect) Imaging

6.2.1.1 Introduction

6.2.1.2 Principle & Procedure

6.2.1.3 Radiotracers

6.2.1.4 Limitations

6.2.1.5 Safety

6.2.1.6 Radiopharmaceuticals

6.2.1.6.1 Technetium-99M

6.2.1.6.2 Gallium (67Ga)

6.2.1.6.3 Sodium Iodide (123I)

6.2.1.6.4 Iobenguane (131I)

6.2.1.6.5 Rhenium (186Re)

6.2.1.6.6 Thallium (201Tl)

6.2.1.6.7 Yttrium (90Y)

6.2.1.6.8 Others

6.2.2 Positron Emission Tomography (Pet) Imaging

6.2.2.1 Introduction

6.2.2.2 Principle & Procedure

6.2.2.3 Radiotracers

6.2.2.4 Limitations

6.2.2.5 Safety

6.2.2.6 Radiopharmaceuticals

6.2.2.6.1 18F-Fd/Fluorodeoxyglucose (18F)

6.2.2.6.2 Others

6.3 Radiopharmaceutical Market, By Indication For Diagnosis

6.3.1 Introduction

6.3.2 Cardiac Diseases

6.3.3 Neuroimaging

6.3.4 Bone Scan

6.3.5 Liver Scan

6.3.6 Respiratory Scan

6.3.7 Renal Scan

6.3.8 Thyroid Scan

6.4 Radiopharmaceuticals For Treatment/Radionuclide Therapy (Rnt)

6.4.1 Targeted Alpha Therapy (Tat) Or Alpha Radioimmunotherapy

6.4.2 Radiopharmaceuticals

6.4.2.1 Iobenguane (131I)

6.4.2.2 Rhenium (186Re)

6.4.2.3 Samarium (153Sm)

6.4.2.4 Erbium (Er169)

6.4.2.5 Others



7 Regulatory Challenges For Radiopharmaceuticals Production

7.1 Introduction

7.2 Safety Of Personnel

7.3 Equipment & Facility

7.4 Transportation Guidelines

7.5 Guidelines In Europe

7.6 Guidelines In U.S.

7.7 Reimbursement



8 Geographic Analysis (Consumption)

8.1 Introduction

8.2 North America

8.2.1 U.S.

8.2.2 Canada

8.3 Europe

8.4 Apac (Excluding Japan)

8.5 Japan

8.6 Rest Of The World (Row)



9 Geographic Analysis (Production)

9.1 Introduction

9.2 North America

9.3 Europe

9.4 Apac (Excluding Japan)

9.5 Japan

9.6 Rest Of The World



10 Competitive Landscape



11 Company Profiles

11.1 Australian Nuclear Association And Technology Organization (Ansto)

11.1.1 Overview

11.1.2 Products & Services

11.1.3 Financials

11.1.4 Strategy

11.1.5 Developments

11.2 Board Of Radiation And Isotope Technology (Brit)

11.2.1 Overview

11.2.2 Products & Services

11.3 Cardinal Health Inc

11.3.1 Overview

11.3.2 Products & Services

11.3.3 Financials

11.3.4 Strategy

11.3.5 Developments

11.4 Covidien Plc

11.4.1 Overview

11.4.2 Products & Services

11.4.3 Financials

11.4.4 Strategy

11.4.5 Developments

11.5 Eczacibasi-Monrol

11.5.1 Overview

11.5.2 Products & Services

11.5.3 Strategy

11.5.4 Financials

11.5.5 Developments

11.6 Fujifilm Holdings Corp

11.6.1 Overview

11.6.2 Products & Services

11.6.3 Financials

11.6.4 Strategy

11.6.5 Developments

11.7 Ge Healthcare

11.7.1 Overview

11.7.2 Products & Services

11.7.3 Financials

11.7.4 Strategy

11.7.5 Developments

11.8 Iba Group

11.8.1 Overview

11.8.2 Products & Services

11.8.3 Financials

11.8.4 Strategy

11.8.5 Developments

11.9 Institute Of Atomic Energy Polatom Radioisotope Centre (Polatom)

11.9.1 Overview

11.9.2 Products & Services

11.9.3 Strategy

11.9.4 Developments

11.10 Institute Of Isotopes Co. Ltd.

11.10.1 Overview

11.10.2 Products & Services

11.10.3 Strategy

11.11 Institute Of Radioelement (Ire)

11.11.1 Overview

11.11.2 Products & Services

11.11.3 Strategy

11.11.4 Developments

11.12 Lantheus Medical Imaging Inc

11.12.1 Overview

11.12.2 Products & Services

11.12.3 Financials

11.12.4 Strategy

11.12.5 Developments

11.13 Nordion Inc.

11.13.1 Overview

11.13.2 Products & Services

11.13.3 Financials

11.13.4 Strategy

11.13.5 Developments

11.14 Ntp Radioisotopes (Pty) Ltd

11.14.1 Overview

11.14.2 Products & Services

11.14.3 Financials

11.14.4 Strategy

11.14.5 Developments

11.15 Samyoung Unitech Co. Ltd

11.15.1 Overview

11.15.2 Products & Services

11.15.3 Financials

11.15.4 Strategy

11.16 Siemens Healthcare

11.16.1 Overview

11.16.2 Products & Services

11.16.3 Financials

11.16.4 Strategy

11.16.5 Developments



Appendix

? U.S. Patents

? Europe Patents

? Japan Patents

? Wipo Patents







List Of Tables



Table 1 Global Radiopharmaceutical Market Revenue, By Applications, 2008 – 2015 ($Million)

Table 2 Radiopharmaceutical Market Revenue, By Geography, 2008 – 2015 ($Million)

Table 3 Radiopharmaceuticals In Clinical Trials

Table 4 Radiopharmaceuticals Segmentation

Table 5 Global Radiopharmaceuticals Market Revenue, By Types, 2008 – 2015 ($Thousand)

Table 6 Radiopharmaceuticals Market Revenue, By Geography, 2008 – 2015 ($Million)

Table 7 North America: Radiopharmaceutical Market Revenue, By Countries, 2008 – 2015 ($Million)

Table 8 Fdg Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 9 North America: Fdg Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 10 Indications Diagnosed By Technetium

Table 11 Technetium Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 12 North America: Technetium Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 13 Thallium Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 14 North America: Thallium Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 15 Gallium Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 16 North America: Gallium Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 17 Sodium Iodide Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 18 North America: Sodium Iodide Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 19 Iobenguane Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 20 North America: Iobenguane Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 21 Rhenium Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 22 North America: Rhenium Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 23 Samarium Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 24 North America: Samarium Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 25 Yttrium Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 26 North America: Yttrium Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 27 Erbium Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 28 North America: Erbium Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 29 Others Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 30 North America: Others Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 31 Global Radiopharmaceuticals Route Of Administration Market Revenue, By Types, 2008 – 2015 ($Million)

Table 32 Radiopharmaceuticals Route Of Administration Market Revenue, By Geography, 2008 – 2015 ($Million)

Table 33 North America: Radiopharmaceuticals Route Of Administration Market Revenue, By Countries, 2008 – 2015 ($Million)

Table 34 Intravenous Route Of Administration Market Revenue, By Geography, 2008 – 2015 ($Million)

Table 35 North America: Intravenous Route Of Administration Market Revenue, By Countries, 2008 – 2015 ($Million)

Table 36 Inhalation Route Of Administration Market Revenue, By Geography, 2008 – 2015 ($Million)

Table 37 North America: Inhalation Route Of Administration Market Revenue, By Countries, 2008 – 2015 ($Million)

Table 38 Peroral Route Of Administration Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 39 North America: Peroral Route Of Administration Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 40 Other Types Of Routes Of Administration

Table 41 Other Routes Of Administration Market Revenue, By Geography, 2008 – 2015 ($Million)

Table 42 North America: Other Routes Of Administration Market, By Countries, 2008 – 2015 ($Million)

Table 43 Global Diagnostic Radiopharmaceuticals Market Revenue, By Types, 2008 – 2015 ($Million)

Table 44 Diagnostic Radiopharmaceuticals Market Revenue, By Geography, 2008 – 2015 ($Million)

Table 45 North America: Diagnostic Radiopharmaceuticals Market, By Countries, 2008 – 2015 ($Million)

Table 46 Global Spect Radiopharmaceuticals Market, By Types, 2008 – 2015 ($Thousand)

Table 47 Spect Radiopharmaceuticals Market Revenue, By Geography, 2008 – 2015 ($Million)

Table 48 North America: Spect Radiopharmaceuticals Market Revenue, By Countries, 2008 – 2015 ($Million)

Table 49 Technetium Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 50 North America: Technetium Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 51 Gallium Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 52 North America: Gallium Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 53 Sodium Iodide Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 54 North America: Sodium Iodide Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 55 Iobenguane Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 56 North America: Iobenguane Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 57 Rhenium Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 58 North America: Rhenium Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 59 Thallium Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 60 North America: Thallium Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 61 Yttrium Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 62 North America: Yttrium Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 63 Others Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 64 North America: Others Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 65 Global Pet Radiopharmaceuticals Market Revenue, By Types, 2008 – 2015 ($Million)

Table 66 Pet Radiopharmaceuticals Market Revenue, By Geography, 2008 – 2015 ($Million)

Table 67 North America: Pet Radiopharmaceuticals Market, By Countries, 2008 – 2015 ($Million)

Table 68 Fdg Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 69 North America: Fdg Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 70 Others Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 71 North America: Others Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 72 Treatment Radiopharmaceuticals Market Revenue, By Types, 2008 – 2015 ($Thousand)

Table 73 Treatment Radiopharmaceuticals Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 74 North America: Treatment Radiopharmaceuticals Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 75 Iobenguane Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 76 North America: Iobenguane Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 77 Rhenium Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 78 North America: Rhenium Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 79 Samarium Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 80 North America: Samarium Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 81 Erbium Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 82 North America Erbium Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 83 Other Radiopharmaceuticals, By Types

Table 84 Others Market Revenue, By Geography, 2008 – 2015 ($Thousand)

Table 85 North America: Others Market Revenue, By Countries, 2008 – 2015 ($Thousand)

Table 86 North America: Radiopharmaceuticals Market Revenue, By Radioisotopes, 2008 – 2015 ($Thousand)

Table 87 U.S: Radiopharmaceuticals Market Revenue, By Radioisotopes, 2008 – 2015 ($Thousand)

Table 88 Canada: Radiopharmaceuticals Market Revenue, By Radioisotopes, 2008 – 2015 ($Thousand)

Table 89 Europe: Radiopharmaceuticals Market Revenue, By Radioisotopes, 2008 – 2015 ($Thousand)

Table 90 Apac: Radiopharmaceuticals Market Revenue, By Radioisotopes, 2008 – 2015 ($Thousand)

Table 91 Japan: Radiopharmaceuticals Market Revenue, By Radioisotopes, 2008 – 2015 ($Thousand)

Table 92 Row: Radiopharmaceuticals Market Revenue, By Radioisotopes, 2008 – 2015 ($Thousand)

Table 93 Mergers & Acquisitions

Table 94 Agreements & Collaborations

Table 95 New Product Development

Table 96 New Expansion Facilities

Table 97 Approvals

Table 98 Ansto Health: Market Revenue, 2008 – 2010 ($Million)

Table 99 Cardinal: Market Revenue, 2008 – 2010 ($Million)

Table 100 Cardinal: Market Revenue, By Segments, 2008 – 2010 ($Million)

Table 101 Covidien: Market Sales And R&D Expenses, 2008 – 2010 ($Million)

Table 102 Covidien: Market Sales, By Segments, 2008 – 2010 ($Million)

Table 103 Covidien: Market Revenue, By Segment, 2008 – 2010 ($Million)

Table 104 Covidien: Revenue, By Geography, 2008 – 2010 ($Million)

Table 105 Fujifilm: Market Revenue, 2009 – 2011 ($Million)

Table 106 Fujifilm: Market Revenue, By Segments, 2009 – 2011 ($Million)

Table 107 Fujifilm: Medical System Segment Revenue, 2009 – 2011 ($Million)

Table 108 Fujifilm: Market Revenue, By Geography, 2009 – 2011 ($Million)

Table 109 Ge Healthcare: Market Revenue And R&D Expenses, 2007 – 2009 ($Billion)

Table 110 Ge Healthcare: Market Revenue, By Segment, 2007 – 2009 ($Billion)

Table 111 Ge Healthcare: Market Revenue, By Geography, 2007 – 2009 ($Billion)

Table 112 Iba Group: Total Market Revenue, 2008 – 2010 ($Million)

Table 113 Iba Group: Market Revenue, By Segments, 2008 – 2010 ($Million)

Table 114 Iba Group: Market Revenue, By Geography, 2008 – 2010 ($Million)

Table 115 Lantheus: Market Revenue And R&D Expenses, 2008 – 2010 ($Thousand)

Table 116 Lantheus: Market Revenue, By Segments, 2008 – 2010 ($Thousand)

Table 117 Lantheus: Market Revenue, By Geography, 2008 – 2010 ($Thousand)

Table 118 Nordion: Market Revenue And R&D Expenses, 2008 – 2010 ($Million)

Table 119 Nordion: Market Revenue, By Segments, 2008 – 2010 ($Million)

Table 120 Nordion: Market Revenue, By Countries, 2008 – 2010 ($Million)

Table 121 Siemens Healthcare: Total Market Revenue, 2008 – 2010 ($Million)

Table 122 Siemens Healthcare: Market Revenue, By Segments, 2008 – 2010 ($Million)





List Of Figures





Figure 1 Radiopharmaceutical Market, By Radioisotopes, 2008 – 2015

Figure 2 Evolution In Radiopharmaceuticals

Figure 3 Radiopharmaceuticals: Market Segmentation

Figure 4 Factors Driving The Radiopharmaceuticals Market

Figure 5 Radiopharmaceutical Market Share Analysis, 2010

Figure 6 Analysis Of Radiopharmaceuticals Market, By End-Users, 2010

Figure 7 Competitive Landscape For Radiopharmaceuticals Market

Figure 8 Patent Analysis, By Assignee, 2005 – 2010

Figure 9 Global Radiopharmaceuticals Market Share, By Production

Figure 10 Global Radiopharmaceuticals Market: Competitive Landscape

Radiopharmaceuticals Therapy and PET/SPECT Imaging Market to reach $4,734 Million by 2015

Radiopharmaceuticals are medical formulations containing radioisotopes and are safe for humans in diagnosis and therapy. Radioisotopes contribute in several sectors of the economy such as food processing, medicine, agriculture, and research. Radioisotopes, in medicine, are used either in liquid form (radiopharmaceuticals) or solid form (sealed source).

Radiopharmaceuticals are defined as the pharmaceuticals that incorporate one or more radioactive isotopes. These are majorly used for diagnostic purposes. Technetium for single photon emission computed tomography (SPECT) and fludeoxyglucose (FDG) for positron emission tomography (PET) are the common radiopharmaceuticals used for diagnosis of various diseases.

Cancer and cardiac mortality have been on the rise. Globally, around 12 million deaths are expected due to cancer by 2030, and approximately 17 million people die due to cardiac diseases every year. Early detection and treatment of cancer can prevent around one-third of the cancer related deaths. In the U.S. alone, around 1.5 million new cases of cancer were reported in 2010. Radiopharmaceuticals such as FDG, samarium, technetium, and others are used in the imaging technologies for the diagnosis of cancer and cardiac diseases. Radiopharmaceuticals help in early and accurate detections of diseases. However, with the increasing incidence of cancer; demand for radiopharmaceuticals used for diagnosis and treatment would also increase.

Question Does this product contain market data for Sr-82?
Answer Please note that Sr-82 is not mentioned in this product.
Question Does this product provide information about potential of isotopes and radiopharmaceuticals in the future?
Answer This product does not provide information about potential of isotopes and radiopharmaceuticals in the future.
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos